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Abstract Clofarabine (40 mg/m
2/day×5) and high-dose
cytosine arabinoside (Ara-C, 1–2 g/m
2/day×5) were used in
10 men and 11 women, at a median age of 45 (22–62)
years, with refractory (N=4) and relapsed (N=17) acute
myeloid leukaemia, after a median of 3 (2–5) prior
regimens. Grade 4 myelosuppression was observed in all
cases, with two patients dying of bacterial sepsis. Nine
patients achieved a complete remission. Disease status,
number of prior therapies, and cytogenetic aberrations were
not associated with the outcome. However, remission was
only achieved with Ara-C at 2 g/m
2/day and not 1 g/m
2/day
(9/15 versus 0/4, P=0.03).
Keywords Clofarabine.Cytosine arabinoside.Refractory.
Relapse.Acute myeloid leukaemia
Introduction
Acute myeloid leukaemia (AML) is an aggressive haema-
tological malignancy affecting mainly adults. The use of
combination chemotherapy is effective and curative in
some patients. The standard induction chemotherapy is a
combination of an anthracycline and standard-dose cyto-
sine arabinoside (Ara-C, 100–200 mg/m
2/day), which
results in a complete remission (CR) rate of 60–70%.
Consolidation or post-remission chemotherapy, with or
without haematopoietic stem cell transplantation (HSCT),
further improves the outcome by decreasing relapses.
However, in primary refractory or relapsed AML, the
prognosis is generally unfavourable, with salvage chemo-
therapy giving a remission rate of merely 10–40%. Factors
predicting a poor outcome include advanced age, adverse
cytogenetic or molecular findings and a short duration of
prior remission in relapsed cases [1].
High-dose Ara-C (1–6 g/m
2/day) alone or in combina-
tion with other drugs is often employed as a salvage
strategy for AML. An intriguing concept in the use of high-
dose Ara-C involves the pre-administration of the purine
analogue fludarabine. In the FLAG regimen (fludarabine,
high-dose Ara-C), fludarabine is first administered, which
activates deoxycytidine kinase, thus enhancing the intracel-
lular conversion of other purine analogues to their active
metabolites. Thereafter, when Ara-C is administered, a
higher intracellular concentration of its active metabolite
Ara-CTP is attained, providing a putative mechanism of
“biochemical modulation” whereby cell killing is increased
[2]. Variations of the FLAG regimen, including FLAG-IDA
(idarubicin), result in a remission rate of 30–50% in
relapsed and refractory AML [3, 4].
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DOI 10.1007/s00277-011-1223-2Clofarabine (2-chloro-2′-fluoro-deoxy-9-β-D-arabino-
furanosyladenosine) is a purine analogue designed to
combine the favourable properties of fludarabine and 2-
chlorodeoxyadenosine [5]. Clofarabine alone or in com-
bination chemotherapy has been shown to be effective in
induction therapy of adult AML, especially in the elderly
population [6–8]. In relapsed or refractory AML, clofarabine
had also shown activity [9]. Because of the structural
similarity between purine analogues, a putative synergism
between clofarabine and Ara-C, similar to that between
fludarabine and Ara-C, has been postulated [10, 11].
In this study, we examined the efficacy and safety of
sequential clofarabine and high-dose Ara-C in relapsed and
refractory AML.
Materials and methods
Patients Consecutive adult patients (≥18 years old) with
primary refractory (failure of ≥2 induction regimens) or
relapsed AML presenting between January 2009 and
August 2010, who had adequate renal and liver functions
(serum creatinine <2×, bilirubin <1.5×, and alanine
aminotransferase and aspirate aminotransferase <10×
upper limits of the reference range) and no active
infection, were studied. Patients gave informed consent.
Cytogenetic abnormalities were categorized according
to the revised Medical Research Council prognostic
classification [12].
Treatment The treatment comprised clofarabine (40 mg/m
2/
day, 1-h intravenous infusion) (Clofarabine Humanitarian
Program, Genzyme Corporation, Cambridge, MA, USA)
and Ara-C (1–2g / m
2/day, 2-h intravenous infusion starting
4 h after clofarabine infusion), given for 5 days. Patients
who achieved CR received further consolidation chemo-
therapy with clofarabine + Ara-C at the same dose and
schedule for a planned two courses, high-dose Ara-C
(3 g/m
2 every 12 h for four doses) or allogeneic HSCT.
Adverse effects were graded according to the World
Health Organization criteria. Standard criteria for response
were adopted.
Statistical analyses Univariate analyses were performed for
the association between response to therapy and disease
status (refractory versus relapsed), age (≤ versus >50 years),
number of prior therapies (≤ versus >2), and cytogenetic
alterations (adverse versus others).
Table 1 Demographical and clinicopathological features of 21 AML patients receiving clofarabine and high-dose cytosine arabinoside
Number Gender Age Remission duration Prior treatment (number) Cytogenetics FLT3 ITD
Primary refractory
4 M=2 49 (34–61)years N.A. 3+7 (N=4) Favourable (N=0) Positive (N=0)
F=2 ICE (N=3) Intermediate (N=2) Negative (N=4)
MTZ + MAra-C (N=3) Adverse (N=2)
FLAG (N=1)
First relapse
11 M=4 45 (22–62)years 5 (2–12)months 3:7 (N=11) Favourable (N=1) Positive (N=1)
F=7 HDAra-C (N=5) Intermediate (N=7) Negative (N=7)
ICE (N=8) Adverse (N=3) Not available (N=3)
MTZ + MAra-C (N=3)
FLAG (N=2)
Allogeneic HSCT (N=2)
Second relapse
6 M=4 44 (22–59)years 4.5 (2–12)months 3:7 (N=6) Favourable (N=0) Positive (N=1)
F=2 HDAra-C (N=3) Intermediate (N=4) Negative (N=4)
ICE (N=6) Adverse (N=1) Not available (N=1)
MTZ + MAra-C (N=3) Not available (N=1)
FLAG (N=1)
Allogeneic HSCT (N=1)
AML acute myeloid leukaemia; age median and range in parenthesis; remission duration time from last remission in relapsed patients, median and
range in parenthesis; FLT3 ITD FLT3 gene internal tandem duplication; M male; F female; N number of patients; 3+7 3 days of daunorubicin
(50 mg/m
2)+7 days of Ara-C (100 mg/m
2); HDAra-C 3 g/m
2 every 12 h for four doses; ICE 5 days of idarubicin (6 mg/m
2), 5 days of Ara-C (600 mg/
m
2), 3 days of etoposide (150 mg/m
2); MTZ + MAra-C 3 days of mitoxantrone (12 mg/m
2)+4 days of Ara-C (1,000 mg/m
2); FLAG 5 days of fludarabine
(30 mg/m
2)+5 days of Ara-C (2,000 mg/m
2); HSCT haematopoietic stem cell transplantation with myeloablative conditioning regimens
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Patients Twenty-one patients (10 men, 11 women) with
de novo (N=20) and secondary (N=1, transformation
from essential thrombocythaemia with JAK2 V617F
mutation) AML, at a median age of 45 (22–62)years,
were treated (Table 1). They had received a median of
three (2–5) prior regimens. There were 4 primary
refractory and 17 relapsed cases. For relapsed patients,
three cases had relapsed from a previous myeloablative
HSCT. The remission duration prior to clofarabine
treatment was short at a median of 5 (2–12)months.
Cytogenetic analyses were performed in 20 patients.
Adverse karyotypes were identified in six patients
(29%). FLT3 gene internal tandem duplication (FLT3-
ITD) was detected in two patients (10%).
Adverse effects The treatment was generally well tolerated.
Common adverse effects included nausea and vomiting
(grade 1/2, N=9, 43%; grade 3, N=2, 10%), rashes (grade
1/2, N=6, 29%) and transient elevation of liver trans-
aminases (grade 1/2, N=12, 57%; grade 3/4, N=2, 10%).
Haematological toxicity was considerable, with all patients
developing grade 4 myelosuppression. Neutropenic fever
occurred in all patients, with bacterial infections docu-
mented in eight cases (38%). Two patients died of
Escherichia coli and Streptococcus viridans septicaemia
on days 9 and 11 of treatment. Therefore, only 19 patients
could be evaluated for response.
Complete remissions Nine patients (7 men, 2 women;
median age, 50; 22–62 years), having received a median
of 3 (2–4) prior regimens, achieved CR (Table 2). These
included two cases with unfavourable karyotypes (t(3;3)
(q21;q26), monosomy 7). All patients had previously
received Ara-C, with nine cases having standard induction
at a median cumulative dose of 1.45 (0.7–16.2)g/m
2, and
three cases having consolidation at a median cumulative
dose of 36 (36–48)g/m
2. Interestingly, for the clofarabine/
Ara-C regimen, all patients achieving remission had
received Ara-C at 2 g/m
2/day, whereas none of the patients
receiving Ara-C at 1 g/m
2/day went into remission. Post-
remission, five patients elected not to receive consolidation
and were still in CR at a median follow-up of 2 (1–4)
months. Three patients underwent allogeneic HSCT, one of
whom had one course of clofarabine + Ara-C as
consolidation pre-transplantation. Two patients were still
in remission; one patient died of post-transplantation
lymphoproliferative disease 4 months afterwards while
still in remission. One patient received two courses of
high-dose Ara-C consolidation, but relapsed 5 months
later.
Table 2 Outcome of 19 AML patients receiving clofarabine and
cytosine arabinoside
Parameters CR NR
Primary refractory (N=4) 2 2
Male 2 0
Female 0 2
Age
≤50 years 0 2
>50 years 2 0
Prior treatment regimens
≤21 0
>2 1 2
Cytogenetic features
Adverse 0 2
Others 2 0
Dose of cytosine arabinoside
1 g/m
2 01
2 g/m
2 21
First relapse (N=11) 5 6
Male 3 1
Female 2 5
Age
≤50 years 4 4
>50 years 1 2
Time from relapse
≤6 months 2 5
>6 months 3 1
Prior treatment regimens
≤21 3
>2 4 3
Cytogenetic features
Adverse 2 1
Others 3 5
Dose of cytosine arabinoside
1 g/m
2 03
2 g/m
2 53
Second relapse (N=4) 2 2
Male 2 0
Female 0 2
Age
≤50 years 2 1
>50 years 0 1
Time from relapse
≤6 months 1 2
>6 months 1 0
Prior treatment regimens
≤21 0
>2 1 2
Cytogenetic features
Adverse 0 1
Others 1 (NA in 1) 1
Dose of cytosine arabinoside
1 g/m
2 00
2 g/m
2 22
NA not available
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patients died subsequently from refractory leukaemia, while
five other patients were alive with the disease.
Prognostic indicators For the whole group, CR was
unrelated to disease status, age, number of prior therapies
and cytogenetic alterations. For relapsed AML, the
response to clofarabine was also not associated with the
duration of prior remission. However, Ara-C at 2 g/m
2/day
was associated with an apparent better outcome than Ara-C
at 1 g/m
2/day (CR, 9/15 versus 0/4, P=0.03, χ
2), although
the number of cases analysed was small.
Discussion
The effectiveness of clofarabine alone or in combination
with other chemotherapeutic drugs has been shown in
induction treatment for adult AML, especially in elderly
patients [6–8]. Besides induction therapy, phase 1 and
phase 2 clinical trials had examined the efficacy of
clofarabine alone [9], or combined with Ara-C and/or
idarubicin, in relapsed or refractory AML [10, 11]. In a
phase 2 study, treatment of refractory and relapsed AML
with clofarabine alone resulted in a CR rate of 41.9% [9].
Another phase 1/2 study of clofarabine (40 mg/m
2/day×5)
plus Ara-C (1 g/m
2/day×5) in relapsed and refractory AML
showed an overall response (including CR without platelet
recovery, CRp) rate of 40% [10]. These results indicated
that clofarabine had significant activity in newly diagnosed
and refractory or relapsed AML. On the other hand, a
recent study by the Southwest Oncology Group in patients
with refractory or relapsed acute lymphoblastic leukaemia
showed that clofarabine (40 mg/m
2/day×5) and Ara-C
(1 g/m
2/day×5) resulted in a CR rate of merely 17% [13].
Hence, the usefulness of clofarabine and Ara-C appears to
be maximal in AML.
Our study showed a high efficacy of clofarabine plus
high-dose Ara-C in refractory or relapsed AML. All our
cases were heavily pre-treated, many with unfavourable
karyotypes. Other traditional salvage regimens were
generally regarded to be ineffective for these patients,
and without innovative regimens, most cases were
candidates for palliative treatment only. On an intention-
to-treat basis, CR was achieved in a remarkable 43% of
patients. Interestingly, Ara-C at 2 g/m
2/day appeared to
result in better outcome than 1 g/m
2/day. The importance of
Ara-C in combination with clofarabine was shown in
another phase 1 study of refractory or relapsed AML,
where clofarabine (15–30 mg/m
2/day×5) plus idarubicin
(12 mg/m
2/day×3) resulted in a CR + CRp rate of 22%,
whereas the addition of Ara-C (1 g/m
2/day×5) improved
the CR rate to 48% [11]. Notably, all of our patients were
previously refractory to or had relapsed from regimens
containing Ara-C at standard to high doses. Moreover,
of four cases where FLAG had failed (Table 1), there
was one CR to clofarabine/Ara-C. Hence, clofarabine/
Ara-C appeared to be still effective in cases otherwise
considered to be refractory to Ara-C. However, further
studies may be required to define the optimal dose of
Ara-C to be used in combination with clofarabine and the
actual margin of clinical benefit derived from the
clofarabine/Ara-C combination as compared with each
of the drugs alone.
The main toxicity of our regimen was myelosuppression.
Two patients died of septicaemia. Therefore, routine use of
myeloid growth factors and aggressive treatment of any
signs of sepsis are needed.
In conclusion, clofarabine plus high-dose Ara-C is a
feasible, safe and efficacious therapy for refractory or
relapsed adult AML. Future studies are needed to examine
the effectiveness of this regimen in induction therapy, and
whether higher doses of Ara-C can be administered safely
and more efficaciously.
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